261 related articles for article (PubMed ID: 17419271)
1. The role of octreotide versus placebo in the prevention of post-ERCP pancreatitis.
Kisli E; Baser M; Aydin M; Guler O
Hepatogastroenterology; 2007; 54(73):250-3. PubMed ID: 17419271
[TBL] [Abstract][Full Text] [Related]
2. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial.
Li ZS; Pan X; Zhang WJ; Gong B; Zhi FC; Guo XG; Li PM; Fan ZN; Sun WS; Shen YZ; Ma SR; Xie WF; Chen MH; Li YQ
Am J Gastroenterol; 2007 Jan; 102(1):46-51. PubMed ID: 17266687
[TBL] [Abstract][Full Text] [Related]
3. Use of octreotide-acetate in preventing pancreatitis-like changes following therapeutic endoscopic retrograde cholangiopancreatography.
Duvnjak M; Supanc V; Simicević VN; Hrabar D; Troskot B; Smircić-Duvnjak L; Bekavac-Beslin M
Acta Med Croatica; 1999; 53(3):115-8. PubMed ID: 10705631
[TBL] [Abstract][Full Text] [Related]
4. The effect of octreotide on the prevention of acute pancreatitis and hyperamylasemia after diagnostic and therapeutic ERCP.
Arvanitidis D; Hatzipanayiotis J; Koutsounopoulos G; Frangou E
Hepatogastroenterology; 1998; 45(19):248-52. PubMed ID: 9496522
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis.
Sternlieb JM; Aronchick CA; Retig JN; Dabezies M; Saunders F; Goosenberg E; Infantolino A; Ionna S; Maislin G; Wright SH
Am J Gastroenterol; 1992 Nov; 87(11):1561-6. PubMed ID: 1279967
[TBL] [Abstract][Full Text] [Related]
6. The value of serum amylase and elastase measurements in the prediction of post-ERCP acute pancreatitis.
Kapetanos D; Kokozidis G; Kinigopoulou P; Xiarchos P; Antonopoulos Z; Progia E; Kitis G
Hepatogastroenterology; 2007 Mar; 54(74):556-60. PubMed ID: 17523321
[TBL] [Abstract][Full Text] [Related]
7. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis.
Thomopoulos KC; Pagoni NA; Vagenas KA; Margaritis VG; Theocharis GI; Nikolopoulou VN
Gastrointest Endosc; 2006 Nov; 64(5):726-31. PubMed ID: 17055865
[TBL] [Abstract][Full Text] [Related]
8. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors.
Christoforidis E; Goulimaris I; Kanellos I; Tsalis K; Demetriades C; Betsis D
Endoscopy; 2002 Apr; 34(4):286-92. PubMed ID: 11932783
[TBL] [Abstract][Full Text] [Related]
9. Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial.
Manolakopoulos S; Avgerinos A; Vlachogiannakos J; Armonis A; Viazis N; Papadimitriou N; Mathou N; Stefanidis G; Rekoumis G; Vienna E; Tzourmakliotis D; Raptis SA
Gastrointest Endosc; 2002 Apr; 55(4):470-5. PubMed ID: 11923756
[TBL] [Abstract][Full Text] [Related]
10. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy.
Arcidiacono R; Gambitta P; Rossi A; Grosso C; Bini M; Zanasi G
Endoscopy; 1994 Nov; 26(9):715-8. PubMed ID: 7536155
[TBL] [Abstract][Full Text] [Related]
11. [Prevention of post-ERCP acute pancreatitis with octreotide].
Baldazzi G; Conti C; Spotti EG; Arisi GP; Scevola M; Gobetti F; Agliardi CM; Galasso P; Bonomi E; Bianchi F
G Chir; 1994; 15(8-9):359-62. PubMed ID: 7803209
[TBL] [Abstract][Full Text] [Related]
12. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial.
Lee KT; Lee DH; Yoo BM
Pancreas; 2008 Nov; 37(4):445-8. PubMed ID: 18953260
[TBL] [Abstract][Full Text] [Related]
13. Pain at 24 hours associated with amylase levels greater than 5 times the upper normal limit as the most reliable indicator of post-ERCP pancreatitis.
Testoni PA; Bagnolo F
Gastrointest Endosc; 2001 Jan; 53(1):33-9. PubMed ID: 11154486
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a rapid urine amylase test using post-ERCP hyperamylasemia as a model.
Hegewald MJ; Isenberg G; Sterling RK; Cooper GS; Chak A; Sivak MV
Am J Gastroenterol; 2001 Sep; 96(9):2640-5. PubMed ID: 11569688
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
Manes G; Ardizzone S; Lombardi G; Uomo G; Pieramico O; Porro GB
Gastrointest Endosc; 2007 Jun; 65(7):982-7. PubMed ID: 17531632
[TBL] [Abstract][Full Text] [Related]
16. Efficacy Versus effectiveness of octreotide in the prophylaxis of post-ERCP pancreatitis.
Andriulli A; Loperfido S
Am J Gastroenterol; 2007 Jul; 102(7):1539. PubMed ID: 17593163
[No Abstract] [Full Text] [Related]
17. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study.
Andriulli A; Caruso N; Quitadamo M; Forlano R; Leandro G; Spirito F; De Maio G
JOP; 2003 Jan; 4(1):41-8. PubMed ID: 12555015
[TBL] [Abstract][Full Text] [Related]
18. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis.
Testoni PA; Mariani A; Masci E; Curioni S
Dig Liver Dis; 2006 Aug; 38(8):588-95. PubMed ID: 16731060
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy for the prevention of post-ERCP pancreatitis.
Foster E; Leung J
Am J Gastroenterol; 2007 Jan; 102(1):52-5. PubMed ID: 17266688
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis.
Masci E; Cavallini G; Mariani A; Frulloni L; Testoni PA; Curioni S; Tittobello A; Uomo G; Costamagna G; Zambelli S; Macarri G; Innocenti P; Dragonetti C;
Am J Gastroenterol; 2003 Oct; 98(10):2182-6. PubMed ID: 14572565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
